基于组学数据对离子通道基因突变致癌机制研究
Research on the Oncogenic Mechanisms of Ion Channel Gene Mutations Based on Multi-Omics Data
摘要: 本研究基于TCGA数据库中多种消化道肿瘤(包括肝细胞癌、胃腺癌、结肠癌、胰腺癌及食管癌)的组学数据,旨在探究离子通道基因突变在肿瘤发生发展中的致癌机制及其对患者预后的影响。研究首先通过严格的质控标准筛选样本,随后利用单因素Cox比例风险回归模型筛选出与患者总生存期显著相关的15个离子通道基因。研究进一步通过共突变分析揭示了这些基因及其家族成员间存在协同与互斥的突变模式,表明它们可能通过形成复杂的调控网络发挥作用。功能富集分析(GO与KEGG)显示,这些基因主要参与离子跨膜转运、膜电位调控等核心生物学过程。最后,通过构建蛋白质–蛋白质相互作用(PPI)网络,研究鉴定出CACNB1、KCNB2、TRPC6等核心枢纽基因。研究结论认为,离子通道基因突变通过破坏细胞离子稳态等机制,在消化道肿瘤的进展中发挥重要作用,并为预后评估和潜在的治疗靶点提供了新的线索。
Abstract: This study utilized multi-omics data from The Cancer Genome Atlas (TCGA) across several gastrointestinal malignancies—including hepatocellular carcinoma, gastric adenocarcinoma, colorectal cancer, pancreatic cancer, and esophageal cancer—to investigate the oncogenic mechanisms of ion channel gene mutations in tumor development and progression, as well as their impact on patient prognosis. First, samples were screened using stringent quality control criteria. Subsequently, univariate Cox proportional hazards regression analysis was applied to identify 15 ion channel genes significantly associated with overall survival. Co-mutation analysis further revealed synergistic and mutually exclusive mutation patterns among these genes and their family members, suggesting that they may function through complex regulatory networks. Functional enrichment analyses (GO and KEGG) indicated that these genes are primarily involved in key biological processes such as transmembrane ion transport and membrane potential regulation. Finally, by constructing a protein-protein interaction (PPI) network, the study identified CACNB1, KCNB2, and TRPC6 as central hub genes. Overall, the findings suggest that mutations in ion channel genes contribute to the progression of gastrointestinal cancers by disrupting cellular ion homeostasis, and they provide new insights for prognostic evaluation and potential therapeutic targets.
文章引用:杨培萱. 基于组学数据对离子通道基因突变致癌机制研究[J]. 世界肿瘤研究, 2026, 16(2): 143-155. https://doi.org/10.12677/wjcr.2026.162016

参考文献

[1] Jin, Y., He, X. and Wu, Y. (2025) Gastrointestinal Cancer: Molecular Pathogenesis and Targeted Therapy. Molecular Biomedicine, 6, Article No. 136. [Google Scholar] [CrossRef
[2] Tanabe, S. (2024) Advances in Molecular Mechanisms of Gastrointestinal Tumors. Cancers (Basel), 16, Article No. 1603.
[3] Smyth, E.C., et al. (2023) Oesophageal Cancer. Nature Reviews Disease Primers, 3, Article No. 17048.
[4] Baccili Cury Megid, T., Farooq, A.R., Wang, X. and Elimova, E. (2023) Gastric Cancer: Molecular Mechanisms, Novel Targets, and Immunotherapies: From Bench to Clinical Therapeutics. Cancers, 15, Article No. 5075. [Google Scholar] [CrossRef] [PubMed]
[5] Patel, A. and Gulhati, P. (2024) Molecular Landscape and Therapeutic Strategies against Colorectal Cancer. Cancers, 16, Article No. 1551. [Google Scholar] [CrossRef] [PubMed]
[6] Park, N.H. and Chung, Y. (2007) Molecular Mechanisms of Hepatitis B Virus-Associated Hepatocellular Carcinoma. The Korean Journal of Hepatology, 13, Article No. 320. [Google Scholar] [CrossRef] [PubMed]
[7] Dong, D., Yu, X., Xu, J., Yu, N., Liu, Z. and Sun, Y. (2024) Cellular and Molecular Mechanisms of Gastrointestinal Cancer Liver Metastases and Drug Resistance. Drug Resistance Updates, 77, Article ID: 101125. [Google Scholar] [CrossRef] [PubMed]
[8] Ren, Y., Ma, Q., Zeng, X., Huang, C., Ren, J., Li, F., et al. (2024) Single-Cell RNA Sequencing Reveals Immune Microenvironment Niche Transitions during the Invasive and Metastatic Processes of Ground-Glass Nodules and Part-Solid Nodules in Lung Adenocarcinoma. Molecular Cancer, 23, Article No. 263. [Google Scholar] [CrossRef] [PubMed]
[9] Prevarskaya, N., Skryma, R. and Shuba, Y. (2018) Ion Channels in Cancer: Are Cancer Hallmarks Oncochannelopathies? Physiological Reviews, 98, 559-621. [Google Scholar] [CrossRef] [PubMed]
[10] Stokłosa, P., Borgström, A., Kappel, S. and Peinelt, C. (2020) TRP Channels in Digestive Tract Cancers. International Journal of Molecular Sciences, 21, Article No. 1877. [Google Scholar] [CrossRef] [PubMed]
[11] Huang, R., Wang, F., Yang, Y., Ma, W., Lin, Z., Cheng, N., et al. (2019) Recurrent Activations of Transient Receptor Potential Vanilloid-1 and Vanilloid-4 Promote Cellular Proliferation and Migration in Esophageal Squamous Cell Carcinoma Cells. FEBS Open Bio, 9, 206-225. [Google Scholar] [CrossRef] [PubMed]
[12] Du, Y., Song, W., Chen, J., Chen, H., Xuan, Z., Zhao, L., et al. (2019) The Potassium Channel KCa3.1 Promotes Cell Proliferation by Activating SKP2 and Metastasis through the EMT Pathway in Hepatocellular Carcinoma. International Journal of Cancer, 145, 503-516. [Google Scholar] [CrossRef] [PubMed]
[13] Lu, S., Dai, M., Hu, X., Yi, H. and Zhang, Y. (2021) A New Survival Model Based on Ion Channel Genes for Prognostic Prediction in Hepatocellular Carcinoma. Genomics, 113, 171-182. [Google Scholar] [CrossRef] [PubMed]
[14] Halima, A., Vuong, W. and Chan, T.A. (2022) Next-Generation Sequencing: Unraveling Genetic Mechanisms That Shape Cancer Immunotherapy Efficacy. Journal of Clinical Investigation, 132, e154945. [Google Scholar] [CrossRef] [PubMed]
[15] Nandakumar, V. and Mills, J.R. (2019) The Now and Beyond of Tumor Mutational Burden as a Predictor of Response to Immune Checkpoint Inhibitors. Clinical Chemistry, 65, Article No. 357. [Google Scholar] [CrossRef] [PubMed]
[16] Wang, X. and Li, M. (2019) Correlate Tumor Mutation Burden with Immune Signatures in Human Cancers. BMC Immunology, 20, Article No. 4. [Google Scholar] [CrossRef] [PubMed]
[17] Marabelle, A., Fakih, M., Lopez, J., Shah, M., Shapira-Frommer, R., Nakagawa, K., et al. (2020) Association of Tumour Mutational Burden with Outcomes in Patients with Advanced Solid Tumours Treated with Pembrolizumab: Prospective Biomarker Analysis of the Multicohort, Open-Label, Phase 2 KEYNOTE-158 Study. The Lancet Oncology, 21, 1353-1365. [Google Scholar] [CrossRef] [PubMed]
[18] Pedersen, S.F. and Stock, C. (2013) Ion Channels and Transporters in Cancer: Pathophysiology, Regulation, and Clinical Potential. Cancer Research, 73, 1658-1661. [Google Scholar] [CrossRef] [PubMed]
[19] Gao, C., Li, H., Liu, C., Xu, X., Zhuang, J., Zhou, C., et al. (2021) Tumor Mutation Burden and Immune Invasion Characteristics in Triple Negative Breast Cancer: Genome High-Throughput Data Analysis. Frontiers in Immunology, 12, Article 650491. [Google Scholar] [CrossRef] [PubMed]
[20] Costa, B.P., Nunes, F.B., Noal, F.C. and Branchini, G. (2022) Ion Channels in Endometrial Cancer. Cancers, 14, Article No. 4733. [Google Scholar] [CrossRef] [PubMed]
[21] Xiong, Z.G. (2011) Ion Channels as Targets for Cancer Therapy. International Journal of Physiology, Pathophysiology and Pharmacology, 3, 156-166.
[22] Moore, A.R., Rosenberg, S.C., McCormick, F. and Malek, S. (2020) RAS-Targeted Therapies: Is the Undruggable Drugged? Nature Reviews Drug Discovery, 19, 533-552. [Google Scholar] [CrossRef] [PubMed]
[23] Fruman, D.A., Chiu, H., Hopkins, B.D., Bagrodia, S., Cantley, L.C. and Abraham, R.T. (2017) The PI3K Pathway in Human Disease. Cell, 170, 605-635. [Google Scholar] [CrossRef] [PubMed]
[24] Shao, Q., Zhang, J. and Wang, H. (2025) cacnb1 Alleviates Mepivacaine-Induced Myocardial Ischemia/Reperfusion Injury by Promoting Nrf2 Nuclear Translocation. Molecular Medicine Reports, 33, Article No. 71. [Google Scholar] [CrossRef
[25] Fan, J.J., Erickson, A.W., Carrillo-Garcia, J., Wang, X., Skowron, P., Wang, X., et al. (2025) A Forward Genetic Screen Identifies Potassium Channel Essentiality in SHH Medulloblastoma Maintenance. Developmental Cell, 60, 1532-1549.e7. [Google Scholar] [CrossRef] [PubMed]
[26] Ge, R., Tai, Y., Sun, Y., Zhou, K., Yang, S., Cheng, T., et al. (2009) Critical Role of TRPC6 Channels in VEGF-Mediated Angiogenesis. Cancer Letters, 283, 43-51. [Google Scholar] [CrossRef] [PubMed]
[27] Lv, Y., Bu, X., Du, Z., Zhang, Y., Si, Y., Shi, H., et al. (2026) Promotion of Lung Cancer Growth via Glutamate Ionotropic Receptor N-Methyl-D-Aspartate-Type Subunit 2D (GRIN2D). Journal of Thoracic Disease, 18, Article No. 36. [Google Scholar] [CrossRef